Discovery of an Orally Bioavailable STING Inhibitor with In Vivo Anti-Inflammatory Activity in Mice with STING-Mediated Inflammation
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Xi Han und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Membrane Proteins, Inflammation. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Natural Science Foundation of Chongqing Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
The cyclic GMP-AMP synthase (cGAS)-stimulator of the interferon genes (STING) pathway plays a key role in triggering interferon and inflammatory responses against microbial invasion or tumor. However, aberrant activation of the cGAS-STING pathway is associated with a variety of inflammatory and autoimmune diseases, and thus inhibition of STING is regarded as a potential new approach to treating these diseases. Herein, we report a series of novel indolyl-urea derivatives as STING inhibitors. The representative compound 42 exhibited potent STING inhibitory activity, acceptable pharmacokinetic properties, and good in vivo safety profiles. Mechanistically, 42 could block the palmitoylation of the STING protein and STING downstream signaling. Importantly, oral administration of 42 could effectively suppress STING-mediated inflammation in 10-carboxymethyl-9-acridanone (CMA)-treated mouse and Trex1-/- mouse. Together, compound 42 represents a promising STING inhibitor for treating STING-associated inflammatory and autoimmune diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
- Chongqing Innovation Institute of China Pharmaceutical University, Chongqing 401135, China.
ORCID-Profile: Xi Han, Qibang Sui, Qinglong Xu, Haoliang Yuan, Hongbin Sun, Liang Dai
Förderung
- Natural Science Foundation of Chongqing Municipality
- National Natural Science Foundation of China
Zitieren
APA
Han, X., Ma, G., Peng, R., Xu, J., Sheng, L., Liu, H., Sui, Q., Li, J., Gu, Y., Yu, J., Feng, Z., Xu, Q., Wen, X., Yuan, H., Sun, H., & Dai, L. (2025). Discovery of an Orally Bioavailable STING Inhibitor with In Vivo Anti-Inflammatory Activity in Mice with STING-Mediated Inflammation. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02200
Vancouver
Han X, Ma G, Peng R, Xu J, Sheng L, Liu H, et al. Discovery of an Orally Bioavailable STING Inhibitor with In Vivo Anti-Inflammatory Activity in Mice with STING-Mediated Inflammation. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02200
BibTeX
@article{Han2025,
author = {Han, Xi and Ma, Guangcai and Peng, Ruikun and Xu, Ju and Sheng, Lixin and Liu, Haohao and Sui, Qibang and Li, Jiaxin and Gu, Yuhao and Yu, Jinli and Feng, Zhiqi and Xu, Qinglong and Wen, Xiaoan and Yuan, Haoliang and Sun, Hongbin and Dai, Liang},
title = {Discovery of an Orally Bioavailable STING Inhibitor with In Vivo Anti-Inflammatory Activity in Mice with STING-Mediated Inflammation},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02200}
}
EUVIMED